How big is Immatics NV?

As of Jun 18, Immatics NV has a market capitalization of 746.32 million, with net sales of 155.29 million and a net profit of -22.90 million over the latest four quarters. Shareholder's funds are 595.25 million, and total assets amount to 720.86 million.

As of Jun 18, Immatics NV has a market capitalization of 746.32 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 155.29 million, while the sum of Net Profit for the same period is -22.90 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 595.25 million and Total Assets at 720.86 million.

What does Immatics NV do?

Immatics NV is a clinical-stage biopharmaceutical company focused on developing T-Cell receptors for targeted cancer therapies. As of March 2025, it has a market cap of $746.32 million, with net sales of $20 million and a net loss of $42 million.

Overview:<BR>Immatics NV is a clinical-stage biopharmaceutical company focused on the discovery and development of T-Cell receptors to enable robust and specific T-Cell responses against targets in the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 20 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -42 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 746.32 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -7.51% <BR>Price to Book: 1.29<BR><BR>Contact Details:<BR>Address: Paul Ehrlich-Strasse 15, TUEBINGEN None: 72076 <BR>Tel: 49 7071 5397700 <BR>Website: https://immatics.com/

Should I buy, sell or hold Immatics NV?

Is Immatics NV overvalued or undervalued?

As of May 13, 2025, Immatics NV is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 1.25 and an unfavorable EV to EBITDA ratio of -2.77, alongside a year-to-date stock return of -23.77% compared to a 2.44% gain in the S&P 500.

As of 13 May 2025, the valuation grade for Immatics NV has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued given its financial metrics and performance relative to peers. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 1.25. Notably, the EV to EBITDA ratio is -2.77, reflecting negative earnings before interest, taxes, depreciation, and amortization.<BR><BR>In comparison to its peers, Immatics NV's valuation appears unfavorable. Protagonist Therapeutics, Inc. has a P/E ratio of 60.90, showcasing a stark contrast in market perception. Other risky peers like Deciphera Pharmaceuticals, Inc. and Geron Corp. have EV to EBITDA ratios of -9.72 and -5.79, respectively, which further highlights Immatics' challenging position. Additionally, the company's stock has underperformed significantly, with a year-to-date return of -23.77%, compared to a 2.44% gain in the S&P 500. Overall, Immatics NV is assessed as overvalued in the current market environment.

Is Immatics NV technically bullish or bearish?

As of October 3, 2025, Immatics NV's trend has shifted to bullish, with strong short-term performance outpacing the S&P 500, though it has underperformed over longer periods.

As of 3 October 2025, the technical trend for Immatics NV has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe. However, the monthly KST is bearish, and the RSI shows no signal on both weekly and monthly timeframes. Overall, the Dow Theory is mildly bullish on both weekly and monthly periods.<BR><BR>In terms of performance, Immatics NV has outperformed the S&P 500 significantly over the past week and month, with returns of 18.71% and 50.00%, respectively, compared to the S&P 500's 1.09% and 4.15%. However, over the longer term, the stock has underperformed against the benchmark in the 1-year, 3-year, 5-year, and 10-year periods.